{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 36 of 74', '10.8 Trial restrictions', 'Women of child-bearing potential are required to use adequate contraception for the', 'duration of treatment and for 4 months after the last dose. This includes:', 'Barrier contraception (condom and occlusive cap e.g. diaphragm or cervical cap', 'with spermicide)', 'True abstinence (where this is in accordance with the patients preferred and', 'usual lifestyle)', 'Please note: If a Hormonal based contraception (pill, contraceptive injection or', 'implant etc) or Intrauterine Device (IUD) is used another method of contraception', 'must also be used as dabrafenib may render hormonal contraceptives less effective', 'Men are required to use adequate contraception for the entire duration of treatment', 'and for 4 months after the last dose. This includes:', 'Barrier contraception (condom and spermicide) even if female partner(s) are', 'using another method of contraception or are already pregnant', 'True abstinence (where this is in accordance with the patients preferred and', 'usual lifestyle)', 'The potential for sperm banking/egg collection should be discussed, where appropriate,', 'according to local practice.', '11 Assessment of Safety', '11.1 Definitions', '11.1.1', 'Adverse event (AE)', 'Any untoward medical occurrence in a patient or clinical trial patient administered a', 'medicinal product and which does not necessarily have a causal relationship with this', 'treatment.', 'An adverse event can therefore be any unfavourable and unintended sign (including', 'an abnormal laboratory finding), symptom, or disease temporally associated with the', 'use of an investigational medicinal product, whether or not considered related to the', 'investigational medicinal product.', 'Please note: Recording of all adverse events must start from the point of Informed', 'Consent regardless of whether a patient has yet received a medicinal product.', '11.1.2', 'Adverse reaction to an investigational medicinal product (AR)', 'All untoward and unintended responses to an investigational medicinal product', 'related to any dose administered. All adverse events judged by either the reporting', 'investigator or the sponsor as having a reasonable causal relationship to a medicinal', 'product qualify as adverse reactions. The expression reasonable causal relationship', 'means to convey in general that there is evidence or argument to suggest a causal', 'relationship.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 37 of 74', '11.1.3', 'Unexpected adverse reaction', 'An adverse reaction, the nature, or severity of which is not consistent with the', 'current approved reference safety information (RSI)', 'When the outcome of the adverse reaction is not consistent with the current', 'approved RSI this adverse reaction should be considered as unexpected.', 'The term \"severe\" is often used to describe the intensity (severity) of a specific', 'event. This is not the same as \"serious,\" which is based on patient/event outcome or', 'action criteria.', '11.1.4', 'Serious adverse event or serious adverse reaction (SAE / SAR)', 'Any untoward medical occurrence that at any dose:', '-', 'results in death,', '-', 'is life-threatening', '-', 'requires hospitalisation or prolongation of existing inpatients hospitalisation,', '-', 'results in persistent or significant disability or incapacity,', '-', 'is a congenital anomaly or birth defect.', '-', 'is an important medical event - Some medical events may jeopardise the patient', 'or may require an intervention to prevent one of the above characteristics/', 'consequences. Such events (hereinafter referred to as `important medical', \"events') should also be considered as 'serious'.\", 'Life-threatening in the definition of a serious adverse event or serious adverse', 'reaction refers to an event in which the patient was at risk of death at the time of', 'event; it does not refer to an event which hypothetically might have caused death if', 'it were more severe.', '11.1.5', 'Suspected Unexpected Serious Adverse Reaction (SUSAR)', 'A serious adverse reaction, the nature and severity of which is not consistent with', 'the information set out in the Reference Safety Information', '11.1.6', 'Reference Safety Information (RSI)', 'The information used for assessing whether an adverse reaction is expected.', 'For the INTERIM trial the Reference Safety Information is contained in the', 'trial-specific RSI document approved by the MHRA for use in this trial and', 'attached as appendix 8 - Reference safety information.', '11.2 Expected Adverse Reactions/Serious Adverse Reactions (AR', '/SARs)', 'All expected Adverse Reactions are listed in the reference safety information contained', 'in Appendix 8 as specified in section 11.1.6. This must be used when making a', 'determination as to the expectedness of the adverse reaction.', 'Use the following tables to determine expectedness:', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}